Selection and structural characterisation of anti-TREM2 scFvs that reduce levels of shed ectodomain
Aleksandra Szykowska, Yu CheniD, Thomas B. SmithiD, Charlotta PregeriD, Jingjing Yang, Dongming QianiD, Shubhashish M. M. MukhopadhyayiD, Edvard WigreniD, Stephen J. NeameiD, S. GräslundiD, Helena PerssoniD, Peter J. AtkinsoniD, Elena Di DanieliD, Emma MeadiD, John C. K. WangiD, John B. Davis, N. Burgess-BrowniD, Alex N. BullockiD
Abstract
Single point mutations in TREM2, a receptor expressed by microglia in the brain, are associated with an increased risk of neurodegeneration including Alzheimers disease. Numerous studies support a role for TREM2 in sensing damaging stimuli and triggering signalling cascades necessary for neuroprotection. Despite its significant role, ligands and regulators of TREM2 activation, and the mechanisms governing TREM2-dependent responses and its cleavage from the membrane, remain poorly characterised. Here, we present phage display generated scFv antibody binders to human TREM2 ectodomain. Cocrystal structures revealed the binding of two scFvs to an epitope on the globular TREM2 domain distal to the putative ligand-binding site. Enhanced functional activity was observed for oligomeric scFv species which inhibited the production of soluble TREM2 in a HEK293 cell model. We hope that detailed characterisation of their epitopes and properties will facilitate the use of these renewable binders as structural and functional biology tools for TREM2 research.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 19
- FWCI
- 1.72
- Field percentile
- top 16%
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Structural and functional analysis of TREM2 interactions with amyloid beta reveal molecular mechanisms that mediate phagocytosis of oligomeric amyloid beta
Jessica A. Greven, Omar Osario, … Tom J. Brett·bioRxiv·May 23, 2024
- Small Molecule Agonists of TREM2 Reprogram Microglia and Protect Synapses in Human Alzheimer's Models
Hossam Nada, Shaoren Yuan, … Moustafa Tarek Gabr·European Journal of Medicinal Chemistry ReportsPeer-reviewed·Jun 9, 2026
- Aβ-Overlapping Ectodomain Binding of the Clinical-Stage TREM2 Agonist VG-3927
Sungwoo Cho, Moustafa Tarek Gabr·bioRxiv·Mar 5, 2026
- Structure-Based Virtual Screening Identifies TREM2-Targeted Small Molecules that Enhance Microglial Phagocytosis
Sungwoo Cho, Baljit Kaur, … Moustafa Tarek Gabr·ChemMedChemPeer-reviewed·Jan 1, 2026
- Wild-type sTREM2 blocks Aβ aggregation and neurotoxicity, while the Alzheimer's R47H mutant does the opposite
A. Vilalta, Y. Zhou, … G. C. Brown·bioRxiv·Dec 3, 2020
- Investigating the therapeutic potential of soluble TREM2 interactions with Transgelin-2 in Alzheimer's disease
David Saeb, Emma E Lietzke, … Kayla G Sprenger·bioRxiv·Nov 2, 2026